- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04004013
Evaluate the Effect of Lifenol in Improving Bone Status in Postmenopausal Osteopenic Women
A Randomised, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effect of Lifenol in Improving Bone Status in Postmenopausal Osteopenic Women
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Osteoporosis is a skeletal disorder characterized by reduced bone mass and deterioration in bone architecture leading to an increased bone fragility and fracture risk. Postmenopausal women are a particularly at-risk population as the maintenance of bone homeostasis is influenced by estrogens. Recently, phytoestrogens have drawn attention as an interesting natural way to prevent oestrogen-deficient osteoporosis. Hops contain one of the most potent phytoestrogen known to date: 8-prenylnaringenin (8-PN). Lifenol® is a polyphenolic powdered extract obtained by a patented process from the female hop flowers (Humulus lupulus L.), standardized in 8-PN content.
Therefore, the present clinical trial aims to determine whether long-term consumption of Lifenol® can reduce bone mineral density loss in postmenopausal women with osteopenia taking traditional recommended calcium and vitamin D supplementation (1000 mg of calcium and 800 IU of vitamin D per day).
100 postmenopausal women (>1 year post-menopause) will be enrolled to consume during 12 months either Lifenol® (dose of 100µg of 8-PN per day) or a placebo. Effect of investigational product will be measured notably on bone density DXA parameters and plasma bone biomarkers.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Cork, Ireland, T23 R50R
- Atlantia Food Clinical Trials
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Be able to give written informed consent;
- Be 50 - 85 years of age;
- Be a free-living postmenopausal (> 1 year post menopause) woman;
- Have a Body Mass Index (BMI) 18 - 32.0 kg/m²;
- Present with a stable weight (+/- 3 kg) for at least the last three (3) months;
- Be a non-smoker
- Maintain existing food and physical activity patterns throughout the study period;
- Present with osteopenia defined as a dual energy X-ray absorptiometry (DXA) T score comprised between -1 and -2.5;
- Be willing to consume the investigational product daily for the duration of the study.
Be able to give written
Exclusion Criteria:
- Are hypersensitive to any of the components of the investigational product;
- Is currently involved in any other clinical trial or having participated in a trial within the preceding 60 days;
- Has a diagnosis of osteoporosis (defined as a T score strictly inferior to -2.5);
- Is currently a smoker;
- Trying to lose weight for the last three (3) months (following a diet or exercise regimen designed for weight loss);
- Recent (within 4 weeks) gastroenteritis or food borne illness;
- Having taken antibiotics or laxatives during the preceding 2 months or anticipated consumption;
- Currently taking (and during the past 3 months) any drug for osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate or denosumab);
- Currently taking (and during the past 3 months) treatment with oestrogen or hormone therapy;
- Currently taking (and during the past 3 months) treatment with oestrogen agonist or antagonist products (raloxifene or tamoxifene);
- Currently taking any supplementation with isoflavones or foods fortified with isoflavones;
- Currently taking (and during the past 4 weeks) any vitamin K supplementation.
- Exhibiting excess alcohol consumption, defined as greater than 11 standard drinks per week for women or drug dependence,
- Has a significant cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder, or metabolic/endocrine disorders or other disease that would preclude supplement ingestion and/or assessment of safety and the study objectives;
- Has a known organic disease, including an inflammatory bowel disease, a benign or malign tumour of intestine or colon and significant systemic disease;
- Has a history of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, or carcinoma in situ with no significant progression over the past 2 years;
- Has uncontrolled hypertension (systolic or diastolic blood pressure superior to 160 and 110 respectively). Subject on hypertension medication, must be on stable medication for 3 months;
- Has uncontrolled hypothyroidism or hyperthyroidism; subject must be stable on medication for 3 months
- Current illnesses which could interfere with the study (e.g. prolonged severe diarrhoea, regurgitation/severe, difficulty swallowing).
- Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Lifenol
50 participants who meet the eligibility criteria will be randomised under active arm and will receive Lifenol product during 12 months
|
Lifenol®, powdered extract obtained from female hops flowers (Humulus lupulus L.) standardized in 8-PN content (100 µg /day) + maltodextrin = 500 mg/capsule + 1000 mg of calcium and 800 IU of vitamin D per day |
Placebo Comparator: Placebo
50 participants who meet the eligibility criteria will be randomised under Placebo arm and will receive placebo product during 12 months
|
Maltodextrin = 500 mg/capsule + 1000 mg of calcium and 800 IU of vitamin D per day |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bone mineral density at the L2-L4 lumbar spine region
Time Frame: baseline and 12 months
|
Change of bone mineral density at L2-L4 lumbar spine region over 12 months.
|
baseline and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bone mineral density at the femoral neck region
Time Frame: baseline, 6 and 12 months
|
DXA scan will provide this parameter
|
baseline, 6 and 12 months
|
Bone mineral content at the L2-4 lumbar spine and femoral neck region
Time Frame: baseline, 6 and 12 months
|
DXA scan will provide this parameter
|
baseline, 6 and 12 months
|
T-score
Time Frame: baseline, 6 and 12 months
|
DXA scan will provide this parameter
|
baseline, 6 and 12 months
|
Fracture risk assessment tool (FRAX) score
Time Frame: baseline, 6 and 12 months
|
FRAX score will be calculated an online tool (university of sheffield frax tool).
|
baseline, 6 and 12 months
|
Plasma bone biomarkers
Time Frame: baseline, 6 and 12 months
|
Change in plasma bone biomarkers will be measured.
|
baseline, 6 and 12 months
|
Plasma prenylflavonoids
Time Frame: baseline, 6 and 12 months
|
Change in plasma prenylflavonoids will be measured.
|
baseline, 6 and 12 months
|
Glucose homeostasis and lipid profile
Time Frame: baseline, 6 and 12 months
|
Change in plasma glucose, insulin and lipids will be measured.
|
baseline, 6 and 12 months
|
Quality of life evaluation
Time Frame: baseline, 3, 6, 9 and 12 months
|
36-item short form (SF-36) will be performed to assess by quality of life.
|
baseline, 3, 6, 9 and 12 months
|
Gastrointestinal tolerance evaluation
Time Frame: baseline, 3, 6, 9 and 12 months
|
Gastrointestinal tolerance of the product will be assessed by the Gastrointestinal Symptom Rating Scale (GSRS).
|
baseline, 3, 6, 9 and 12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AFCRO-100
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteopenia, Generalized
-
National and Kapodistrian University of AthensNational Hellenic Research FoundationCompletedOsteopenia | Postmenopausal OsteopeniaGreece
-
Chinese PLA General HospitalBeijing Jishuitan Hospital; Beijing Aerospace General HospitalUnknownOsteoporosis | Osteopenia, OsteoporosisChina
-
NestléInstitut National de la Recherche Agronomique; Centre de Recherche en Nutrition...CompletedOsteoporosis, OsteopeniaFrance
-
Instituto de Investigación Hospital Universitario...Completed
-
MeddocThe Research Council of Norway; TineRecruitingOsteopenia or OsteoporosisNorway
-
Hofseth Biocare ASAMøre og Romsdal Hospital TrustActive, not recruitingOsteopenia | Osteopenia of the ElderlyNorway
-
Aarhus University HospitalCompleted
-
Umm Al-Qura UniversityCompletedOsteopenia or OsteoporosisSaudi Arabia
-
Umm Al-Qura UniversityCompletedOsteopenia or OsteoprosisSaudi Arabia
-
Hoffmann-La RocheCompletedPost-Menopausal OsteopeniaFrance
Clinical Trials on Lifenol®
-
Galderma R&DCompletedAtopic DermatitisPhilippines, China
-
Dong-A ST Co., Ltd.CompletedFunctional DyspepsiaKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompleted
-
Chung-Ang University Hosptial, Chung-Ang University...UnknownFunctional DyspepsiaKorea, Republic of
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Diphtheria | PolioUnited States
-
Amir AzarpazhoohInstitut Straumann AGCompletedPeriodontal Inflammation | Crown LengtheningCanada
-
Novartis PharmaceuticalsCompletedPulmonary Disease, Chronic Obstructive (COPD)Argentina
-
GuerbetCompletedPrimary Brain TumorColombia, Korea, Republic of, United States, Mexico
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussisUnited States